Artiva Biotherapeutics (ARTV) Competitors $2.04 +0.25 (+13.97%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.98 -0.06 (-3.19%) As of 07/11/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV vs. ACRS, BIOA, MOLN, ALEC, VTYX, LXEO, THTX, BDTX, ALTS, and LYELShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors Aclaris Therapeutics BioAge Labs Molecular Partners Alector Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Artiva Biotherapeutics (NASDAQ:ARTV) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Is ARTV or ACRS more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -732.42%. Aclaris Therapeutics' return on equity of -30.73% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A -75.95% -39.51% Aclaris Therapeutics -732.42%-30.73%-22.74% Do analysts rate ARTV or ACRS? Artiva Biotherapeutics presently has a consensus target price of $17.80, suggesting a potential upside of 772.55%. Aclaris Therapeutics has a consensus target price of $8.71, suggesting a potential upside of 455.05%. Given Artiva Biotherapeutics' higher probable upside, research analysts clearly believe Artiva Biotherapeutics is more favorable than Aclaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Do institutionals and insiders believe in ARTV or ACRS? 98.3% of Aclaris Therapeutics shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ARTV or ACRS? In the previous week, Aclaris Therapeutics had 4 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 1 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.87 beat Aclaris Therapeutics' score of 0.85 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Artiva Biotherapeutics Very Positive Aclaris Therapeutics Positive Which has preferable earnings and valuation, ARTV or ACRS? Artiva Biotherapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$250K198.78-$65.37MN/AN/AAclaris Therapeutics$18.72M9.08-$132.07M-$1.39-1.13 SummaryAclaris Therapeutics beats Artiva Biotherapeutics on 8 of the 14 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.61M$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E RatioN/A20.5827.9620.25Price / Sales198.78291.28430.5799.61Price / CashN/A42.8637.4658.16Price / Book0.277.638.045.49Net Income-$65.37M-$55.05M$3.18B$250.27M7 Day Performance24.01%8.39%3.63%4.75%1 Month Performance-0.49%5.35%4.04%7.64%1 Year PerformanceN/A1.95%29.56%16.34% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics3.0297 of 5 stars$2.04+14.0%$17.80+772.5%N/A$43.61M$250K0.0081Positive NewsHigh Trading VolumeACRSAclaris Therapeutics2.224 of 5 stars$1.46+1.4%$9.71+565.4%+24.6%$155.93M$18.72M-1.05100Analyst ForecastGap UpBIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/AMOLNMolecular Partners3.1095 of 5 stars$3.61-4.0%$12.00+232.4%-47.1%$151.81M$2.23M-1.88180ALECAlector3.9984 of 5 stars$1.44-4.6%$4.00+177.8%-70.2%$150.99M$100.56M-1.14270News CoveragePositive NewsVTYXVentyx Biosciences3.5301 of 5 stars$2.04-1.9%$10.00+390.2%+10.9%$148.01MN/A-1.1730News CoverageLXEOLexeo Therapeutics2.3536 of 5 stars$4.54+2.0%$16.60+265.6%-74.4%$147.73M$650K-1.3858High Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+117.2%$147.14M$85.87M-39.63140Positive NewsEarnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.769 of 5 stars$2.50-3.1%$12.80+412.0%-46.8%$146.71MN/A41.6790News CoveragePositive NewsALTSALT5 Sigma0.1206 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma3.5059 of 5 stars$9.15-5.6%$15.00+63.9%-71.3%$143.49M$60K-0.37270Positive News Related Companies and Tools Related Companies ACRS Alternatives BIOA Alternatives MOLN Alternatives ALEC Alternatives VTYX Alternatives LXEO Alternatives THTX Alternatives BDTX Alternatives ALTS Alternatives LYEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTV Stock Alerts